In this episode of Speaking of SurgOnc®, Rick Greene, MD, and Judy Boughey, MD, discuss the impact of COVID-19 on US clinical research at the local, cooperative group, and national level. Dr. Boughey is the author of the article, “Impact of the COVID-19 Pandemic on Cancer Clinical Trials.” Dr. Judy Boughey is Professor of Surgery in Division of Breast and Melanoma Surgical Oncology, Department of Surgery at Mayo Clinic, Rochester, MN.

Speaking of SurgOnc

Impact of the COVID-19 Pandemic on Cancer Clinical Trials

Rick Greene, MD, and Elisa Port, MD, discuss surgeon adherence to NCCN guidelines and patterns of testing in newly diagnosed breast cancer patients. Dr. Port is author of, “Adherence to NCCN Guidelines for Genetic Testing in Breast Cancer Patients: Who Are We Missing?” Dr. Port is Chief of Breast Surgery and Director of the Dubin Breast Center, Mount Sinai Hospital, and  Professor of Surgery, Icahn School of Medicine at Mount Sinai, New York, New York.

Adherence to NCCN Guidelines for Genetic Testing in Breast Cancer Patients: Who Are We Missing?

Rick Greene, MD and Nancy Cho, MD discuss the impact of the 2015 American Thyroid Association guideline change on clinical practice in low-risk differentiated thyroid cancer, specifically regarding the rate of completion thyroidectomy. Dr. Cho is author of the article, “Completion Thyroidectomy is Less Common Following Updated 2015 American Thyroid Association Guidelines.” Dr. Cho is Associate Surgeon, Brigham and Women's Hospital and Dana-Farber Cancer Institute, and Assistant Professor of Surgery, Harvard Medical School, Boston, MA.

Completion Thyroidectomy is Less Common Following Updated 2015 American Thyroid Association Guidelines

Rick Greene, MD, and Courtney Balentine, MD, discuss race and gender disparities in the time from initial diagnosis of hyperparathyroidism to treatment with parathyroidectomy. Dr. Balentine is author of, "Race and Gender Disparities in Access to Parathyroidectomy: A Need to Change Processes for Diagnosis and Referral to Surgeons." Dr. Balentine is Assistant Professor of General and Endocrine Surgery, and Co-Director of the UTSW Surgical Center for Outcomes, Implementation and Novel Interventions (S-COIN), University of Texas Southwestern and VA North Texas Healthcare System, Dallas, TX.

Race and Gender Disparities in Access to Parathyroidectomy: A Need to Change Processes for Diagnosis and Referral to Surgeons

Rick Greene, MD and Vivian Strong, MD discuss factors associated with quality-of-life recovery after gastrectomy. Dr. Strong is author of “Longitudinal Analysis of Quality-of-Life Recovery After Gastrectomy for Cancer.” Dr. Strong is the Iris Cantor Endowed Chair and Attending Surgeon, Memorial Sloan Kettering Cancer Center; Professor of Surgery and Associate Dean, Weill Cornell Medical College of Cornell University; and Vice Chair of Surgery for Surgical Innovations and Outcomes, Memorial Sloan Kettering Cancer Center, New York, NY.

Longitudinal Analysis of Quality-of-Life Recovery After Gastrectomy for Cancer

Rick Greene, MD, and Melissa Hogg, MD, discuss the relationship of serum CA19-9 to other markers of response, and the related thresholds correlating to outcomes, following neoadjuvant therapy for pancreatic adenocarcinoma. Dr. Hogg is author of the article, “Serum CA19-9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Adenocarcinoma.” Dr. Hogg is the Director of HPB Surgery and Director of Robotic Training for Grainger Lab at the Northshore University Healthsystem, Chicago, IL.

Serum CA19-9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Adenocarcinoma

Rick Greene, MD, and Ken Tanabe, MD, discuss the need for surgical oncologists to remain focused on providing optimal care for our cancer patients while managing the demands that the COVID-19 pandemic continues to impose. Dr. Tanabe is author of, "Surgical Oncologists and the COVID-19 Pandemic: Guiding Cancer Patients Effectively through Turbulence and Change." Dr. Tanabe is a Professor of Surgery at Harvard Medical School and Chief, Division of Gastrointestinal and Oncologic Surgery, Massachusetts General Hospital. Dr. Tanabe is also Deputy Editor of the Annals of Surgical Oncology.

Surgical Oncologists and the COVID-19 Pandemic: Guiding Cancer Patients Effectively through Turbulence and Change

Rick Greene, MD and Charlotte Ariyan, MD, PhD, discuss survival outcomes in patients with metastatic melanoma who were selected for surgery following checkpoint blockade. Dr. Ariyan is author of, “Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade.” Dr. Ariyan is Associate Professor of Surgery, Weill Cornell Medical College, and a Surgeon with clinical expertise in melanoma and soft tissue sarcoma, at Memorial Sloan Kettering Cancer Center, New York, NY. Dr. Ariyan is also Section Editor, Sarcoma, at the Annals of Surgical Oncology.

Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade

Rick Greene, MD and Katie Egan, MD discuss the use of an educational intervention to decrease opioid consumption among breast surgery patients. Dr. Egan is author of the article, “Opioid Consumption Following Breast Surgery Decreases with a Brief Educational Intervention: A Randomized, Controlled Trial.” Dr. Egan is Plastic and Reconstructive Surgery Resident at The University of Kansas Medical Center in Kansas City, KS.

Opioid Consumption Following Breast Surgery Decreases with a Brief Educational Intervention: A Randomized, Controlled Trial

Rick Green, MD and Dr. Anna Weiss, MD discuss clinical trials that have defined the role of neoadjuvant endocrine therapy in patients with estrogen receptor-positive breast cancer. Dr. Weiss is author of “The Landmark Series: Neoadjuvant Endocrine Therapy for Breast Cancer.” Dr. Weiss is Assistant Professor of Surgery at Harvard Medical School, Boston, MA.

The Landmark Series: Neoadjuvant Endocrine Therapy for Breast Cance

Rick Greene, MD, and Alexandra Gangi, MD and James Howe, MD, discuss current data regarding management of neuroendocrine liver metastases and future areas for study. Dr. Gangi and Dr. Howe are authors of “The Landmark Series: Neuroendocrine Tumor Liver Metastases.” Dr. Gangi is Assistant Professor of Surgery in the Department of Surgical Oncology and the Director of the Gastrointestinal Tumor Program at Cedars-Sinai, Los Angeles, CA. Dr. James Howe is Professor of Surgery and Division Head of Surgical Oncology and Endocrine Surgery, University of Iowa Hospitals & Clinics, Iowa City, IA. Dr. Howe is also President of the North American Neuroendocrine Tumor Society and President of the Society of Surgical Oncology.

The Landmark Series: Neuroendocrine Tumor Liver Metastases

Rick Greene, MD and Giorgos Karakousis, MD discuss the impact of immune checkpoint and BRAF/MEK pathway inhibitors on outcomes and melanoma care at a national population level in patients diagnosed with clinical stage III melanoma. Dr. Karakousis is author of, “Survival Outcomes of Patients with Clinical Stage III Melanoma in the Era of Novel Systemic Therapies.” Dr. Karakousis is Associate Professor of Surgery at the Hospital of the University of Pennsylvania, Philadelphia, PA.

Survival Outcomes of Patients with Clinical Stage III Melanoma in the Era of Novel Systemic Therapies

Rick Greene, MD, and Michael D’Angelica, MD discuss the relationship between hepatic parenchymal disease and recurrence after colorectal liver metastases resection, which has not been well defined. Dr. D’Angelica is author of, “Prediction of Recurrence Patterns from Hepatic Parenchymal Disease After Resection of Colorectal Liver Metastases.” Dr. D’Angelica holds the Enid A. Haupt Chair in Surgery at Memorial Sloan Kettering Cancer Center and is Professor of Surgery at Weill Medical College of Cornell University, New York.

Prediction of Recurrence Patterns from Hepatic Parenchymal Disease After Resection of Colorectal Liver Metastases

Rick Greene, MD and Elizabeth Grubbs, MD, MS discuss an analysis of the applicant pool of complex general surgical oncology (CGSO) fellowships and how it has changed over the last decade. Dr. Grubbs is author of, “Complex General Surgical Oncology Fellowship Applicants: Trends over Time and the Impact of Board Certification Eligibility.” Dr. Grubbs is Associate Professor, Program Director of Complex General Surgical Oncology Fellowship, Vice Chair of Education, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX.

Complex General Surgical Oncology Fellowship Applicants: Trends over Time and the Impact of Board Certification Eligibility

Rick Greene, MD and Julie Hallet, MD discuss the moderate-to-severe symptoms observed to steeply increase as death nears for patients with neuroendocrine tumors (NETs), which highlight an opportunity for improved management. Dr. Hallet is author of, “Symptom Burden at the End of Life for Neuroendocrine Tumors: An Analysis of 2579 Prospectively Collected Patient-Reported Outcomes.” Dr. Hallet is Assistant Professor, Surgical Oncology, University of Toronto and Sunnybrook Health Sciences Centre, Toronto, Canada.

Symptom burden at the end-of-life for neuroendocrine tumors: an analysis of 2,579 prospectively collected patient-reported outcomes

"Speaking of SurgOnc" is a podcast series brought to you by the Annals of Surgical Oncology (ASO) and the Society of Surgical Oncology(SSO). Dr. Frederick L. (Rick) Greene, ASO Deputy Editor, will explore and expand upon ideas and concepts described in articles published in the Annals of Surgical Oncology. Dr. Greene will interview authors and leading experts about topics of current importance in surgical oncology.

hubhopper

Speaking of SurgOnc

hubhopper